Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib [0.03%]
EGFR突变阳性晚期肺腺癌一线使用奥希替尼的失败模式、局部治疗的影响以及长期应答者的特征分析
Allen C C Chen,Florence S T Mok,Wesley K Y Wong et al.
Allen C C Chen et al.
Introduction: Recent randomized trials demonstrate that intensified therapy improves progression-free survival (PFS) and overall survival (OS)compared to osimertinib monotherapy in advancedEGFRmutant non-small cell lung c...
Overall survival in patients with non-small cell lung cancer and leptomeningeal metastases: Data from the Dutch cancer Registry [0.03%]
荷兰癌症登记处非小细胞肺癌伴脑膜转移患者的总生存期数据
Jarno W J Huijs,Francesca R Ogliari,Ronald A M Damhuis et al.
Jarno W J Huijs et al.
Background: Leptomeningeal metastases (LM) at initial diagnosis are a rare manifestation in patients with non-small cell lung cancer (NSCLC), historically associated with poor survival and limited treatment options. With ...
Patient preferences for EGFR mutation-targeted therapies in non-small cell lung cancer, with a focus on Exon 20 insertions [0.03%]
非小细胞肺癌患者EGFR突变靶向治疗的偏好分析——聚焦 exon20插入突变患者
Jaein Seo,Eileen Curran,Jennifer A Whitty et al.
Jaein Seo et al.
Introduction: This study investigated treatment preferences of patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations, e.g., exon 20 insertion (ex20ins), and assessed the tr...
Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation [0.03%]
KRAS或EFGR突变型肺腺癌脑转移的模式及其与生存期的关系
Martin Faehling,Sabine Fallscheer,Julia Schmiederer et al.
Martin Faehling et al.
Background: NSCLC with mutations of the KRAS or EGFR gene is associated with a high risk of brain metastases (BRA). There are few data on the prevalence and pattern of BRA and on survival in unselected KRAS or EGFR patien...
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study [0.03%]
不可切除的III期EGFR突变型非小细胞肺癌患者接受同期放化疗后的体现实验、治疗模式和预后：一项全球真实世界研究的最终分析
Myung-Ju Ahn,Steven H Lin,Cheng-Ta Yang et al.
Myung-Ju Ahn et al.
Introduction: In the phase III LAURA study, osimertinib after definitive chemoradiotherapy (CRT) demonstrated a statistically significant, clinically meaningful progression-free survival (PFS) benefit over placebo in pati...
Prognostic impact of pleural lavage cytology in EGFR-stratified resected non-small cell lung cancer [0.03%]
EGFR分型非小细胞肺癌患者胸水细胞学的预后价值
Naoya Ishibashi,Hideyuki Nagata,Ryuga Yabe et al.
Naoya Ishibashi et al.
Introduction: Positive pleural lavage cytology (PLC) indicates microscopic pleural dissemination and is associated with poor prognosis; however, it is not incorporated into the current TNM staging system and rarely guides...
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study [0.03%]
奥希替尼一线治疗后二线卡铂联合培美曲塞治疗EGFR突变型晚期NSCLC的真实世界预后：一项国际多中心队列研究
Igor Gomez-Randulfe,Federico Monaca,Ornella Cantale et al.
Igor Gomez-Randulfe et al.
Background: First-line osimertinib is one of the standards of care for EGFR-mutant advanced non-small cell lung cancer (NSCLC), but most patients eventually progress. After progression, carboplatin plus pemetrexed remains...
Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults [0.03%]
儿童肺癌的基因组特点：与成人相比，ALK融合及TP53突变频率较高
Michael Abele,Anton Karelin,Michaela Pogoda et al.
Michael Abele et al.
Background: Primary lung carcinomas are extremely rare in childhood, resulting in limited knowledge of their biology and potential therapeutic targets. Me...
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial [0.03%]
YK-029A治疗既往经治EGFR T790M突变NSCLC的I期临床试验的安全性和有效性：一项多中心研究
Xinyu Wu,Rui Wan,Lin Wu et al.
Xinyu Wu et al.
Introduction: YK-029A is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Previous studies have shown promising efficacy and tolerability in treatment-naïve patients with ...
Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies [0.03%]
艾乐替尼治疗后使用brigatinib的疗效和安全性：ALTA-2研究与J-ALTA研究综合分析
Tony Mok,Makoto Nishio,Tatsuya Yoshida et al.
Tony Mok et al.
Objectives: Alectinib is a first-line treatment for ALK + NSCLC. There is a lack of evidence guiding treatment after disease progression on alectinib. This integrated analysis of two phase 2 trials evaluated efficacy and ...